California Pacific Medical Center
- Type
- Teaching hospital
- Where
- SAN FRANCISCO, CA
- Medicare CCN
- 050047
- Received
- $1,180,921 in 74 records, 2025 ($10,682 general, $1,170,238 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Patent assignee: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 4 | $10,682 |
| 2025 | Research payment | 70 | $1,170,238 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 7 | $919,332 | 2025 |
| ABBVIE INC. | 24 | $125,935 | 2025 |
| PTC Therapeutics, Inc. | 3 | $38,369 | 2025 |
| Regeneron Pharmaceuticals, Inc. | 6 | $34,287 | 2025 |
| ARGENX US, INC. | 20 | $25,954 | 2025 |
| CSL Behring | 7 | $20,733 | 2025 |
| Incyte Corporation | 1 | $7,999 | 2025 |
| Medtronic, Inc. | 1 | $2,888 | 2025 |
| Organon Llc | 2 | $2,736 | 2025 |
| Chiesi USA, Inc. | 1 | $1,500 | 2025 |
| Cochlear Americas | 1 | $1,153 | 2025 |
| Medline Industries LP | 1 | $29 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 70 | $1,170,238 |
| Space rental or facility fees (teaching hospital only) | 2 | $9,499 |
| Long term medical supply or device loan | 1 | $1,153 |
| Debt forgiveness | 1 | $29 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | $501,334 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | STUDY NAME#Phase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologo | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $135,921 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $37,894 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $22,662 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRP | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $350 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2025 |
| 2025-12-31 | Medline Industries LP | $29 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-30 | ABBVIE INC. | $18,658 | Research payment | Cash or cash equivalent | EPKINLY Drug, ONCOLOGY | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2025 |
| 2025-12-22 | Merck Sharp & Dohme LLC | $214,308 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombin | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | $5,524 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Res | 2025 |
| 2025-12-11 | ABBVIE INC. | $7,450 | Research payment | Cash or cash equivalent | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participa | 2025 | |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $1,741 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R376 | 2025 |
| 2025-12-08 | ABBVIE INC. | $3,750 | Research payment | Cash or cash equivalent | A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Scl | 2025 | |
| 2025-12-01 | ABBVIE INC. | $7,000 | Research payment | Cash or cash equivalent | A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Scl | 2025 | |
| 2025-12-01 | ARGENX US, INC. | $70 | Research payment | In-kind items and services | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2025 |
| 2025-11-04 | ABBVIE INC. | $4,657 | Research payment | Cash or cash equivalent | EPKINLY Drug, ONCOLOGY | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2025 |
| 2025-11-01 | ARGENX US, INC. | $70 | Research payment | In-kind items and services | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2025 |
| 2025-10-29 | ARGENX US, INC. | $2,100 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar | 2025 |
| 2025-10-29 | ARGENX US, INC. | $1,000 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar | 2025 |
| 2025-10-29 | ARGENX US, INC. | $750 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar | 2025 |
| 2025-10-29 | ARGENX US, INC. | $550 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar | 2025 |
| 2025-10-29 | ARGENX US, INC. | $550 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar | 2025 |
| 2025-10-29 | ARGENX US, INC. | $150 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar | 2025 |
| 2025-10-23 | Regeneron Pharmaceuticals, Inc. | $8,489 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Res | 2025 |
| 2025-10-13 | Merck Sharp & Dohme LLC | $6,861 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 and Lenvatin | 2025 |
| 2025-10-03 | CSL Behring | $64 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2025 | |
| 2025-10-01 | ARGENX US, INC. | $70 | Research payment | In-kind items and services | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2025 |
| 2025-09-25 | ABBVIE INC. | $15,639 | Research payment | Cash or cash equivalent | ELAHERE Drug, ONCOLOGY | Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Pla | 2025 |
| 2025-09-25 | ABBVIE INC. | $600 | Research payment | Cash or cash equivalent | EPKINLY Drug, ONCOLOGY | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2025 |
| 2025-09-24 | Organon Llc | $2,500 | Research payment | Cash or cash equivalent | 7339-007 | 2025 | |
| 2025-09-15 | Organon Llc | $236 | Research payment | Cash or cash equivalent | 7902-003 | 2025 | |
| 2025-09-04 | ABBVIE INC. | $2,250 | Research payment | Cash or cash equivalent | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participa | 2025 | |
| 2025-09-03 | ABBVIE INC. | $3,034 | Research payment | Cash or cash equivalent | EPKINLY Drug, ONCOLOGY | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2025 |
| 2025-09-01 | ARGENX US, INC. | $70 | Research payment | In-kind items and services | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2025 |
| 2025-08-12 | ABBVIE INC. | $134 | Research payment | Cash or cash equivalent | EPKINLY Drug, ONCOLOGY | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2025 |
| 2025-08-11 | ABBVIE INC. | $340 | Research payment | Cash or cash equivalent | A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Scl | 2025 | |
| 2025-08-11 | ABBVIE INC. | $131 | Research payment | Cash or cash equivalent | A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Scl | 2025 | |
| 2025-08-05 | ABBVIE INC. | $3,270 | Research payment | Cash or cash equivalent | EPKINLY Drug, ONCOLOGY | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2025 |
| 2025-08-01 | ARGENX US, INC. | $70 | Research payment | In-kind items and services | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2025 |
| 2025-07-23 | ARGENX US, INC. | $2,000 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgar | 2025 |
| 2025-07-10 | ABBVIE INC. | $4,932 | Research payment | Cash or cash equivalent | EPKINLY Drug, ONCOLOGY | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2025 |
| 2025-07-07 | ABBVIE INC. | $3,519 | Research payment | Cash or cash equivalent | A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Scl | 2025 | |
| 2025-07-02 | ABBVIE INC. | $3,902 | Research payment | Cash or cash equivalent | EPKINLY Drug, ONCOLOGY | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2025 |
| 2025-07-01 | ARGENX US, INC. | $70 | Research payment | In-kind items and services | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2025 |
| 2025-06-30 | PTC Therapeutics, Inc. | $31,910 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK | 2025 | |
| 2025-06-18 | Chiesi USA, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KENGREAL Drug, CARDIOVASCULAR | 2025 | |
| 2025-06-10 | Cochlear Americas | $1,153 | Long term medical supply or device loan | In-kind items and services | COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution | 2025 | |
| 2025-06-04 | ABBVIE INC. | $15,639 | Research payment | Cash or cash equivalent | ELAHERE Drug, ONCOLOGY | Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Pla | 2025 |
| 2025-06-03 | ABBVIE INC. | $1,742 | Research payment | Cash or cash equivalent | EPKINLY Drug, ONCOLOGY | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2025 |
| 2025-06-01 | ARGENX US, INC. | $70 | Research payment | In-kind items and services | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2025 |
| 2025-05-09 | ABBVIE INC. | $3,410 | Research payment | Cash or cash equivalent | A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Scl | 2025 | |
| 2025-05-07 | ABBVIE INC. | $3,522 | Research payment | Cash or cash equivalent | EPKINLY Drug, ONCOLOGY | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2025 |
| 2025-05-01 | ARGENX US, INC. | $70 | Research payment | In-kind items and services | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2025 |
| 2025-04-30 | PTC Therapeutics, Inc. | $994 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK | 2025 | |
| 2025-04-28 | CSL Behring | $4,186 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2025 | |
| 2025-04-09 | ABBVIE INC. | $8,051 | Research payment | Cash or cash equivalent | A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Scl | 2025 | |
| 2025-04-03 | ABBVIE INC. | $10,757 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Co | 2025 | |
| 2025-04-01 | ARGENX US, INC. | $70 | Research payment | In-kind items and services | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2025 |
| 2025-03-28 | Medtronic, Inc. | $2,888 | Research payment | Cash or cash equivalent | ONYX 18 Device, Liquid Embolics | EMBOLISE | 2025 |
| 2025-03-21 | Incyte Corporation | $7,999 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2025 | |
| 2025-03-03 | ABBVIE INC. | $3,410 | Research payment | Cash or cash equivalent | A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Scl | 2025 | |
| 2025-03-01 | ARGENX US, INC. | $70 | Research payment | In-kind items and services | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2025 |
| 2025-02-27 | PTC Therapeutics, Inc. | $5,464 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK | 2025 | |
| 2025-02-25 | ARGENX US, INC. | $18,014 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2025 |
| 2025-02-18 | CSL Behring | $8,550 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2025 | |
| 2025-02-18 | CSL Behring | $4,500 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2025 | |
| 2025-02-18 | CSL Behring | $550 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2025 | |
| 2025-02-18 | CSL Behring | $182 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2025 | |
| 2025-02-11 | CSL Behring | $2,700 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2025 | |
| 2025-02-01 | ARGENX US, INC. | $70 | Research payment | In-kind items and services | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2025 |
| 2025-01-09 | Regeneron Pharmaceuticals, Inc. | $14,050 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2025 |
| 2025-01-09 | ABBVIE INC. | $129 | Research payment | Cash or cash equivalent | M24-147 - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmonipl | 2025 | |
| 2025-01-07 | Regeneron Pharmaceuticals, Inc. | $4,347 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2025 |
| 2025-01-07 | Regeneron Pharmaceuticals, Inc. | $135 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2025 |
| 2025-01-01 | ARGENX US, INC. | $70 | Research payment | In-kind items and services | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.
| Measure | Place (city or town) San Francisco, CA | County San Francisco County, CA | State California |
|---|---|---|---|
| Population B01003 | 830,235 | 830,235 | 39,287,377 |
| Population, 2020 census P1 | 873,965 | 873,965 | 39,538,223 |
| Median age B01002 | 40.0 | 40.0 | 37.9 |
| Under 18 B01001 | 13.7% | 13.7% | 22.0% |
| 65 and over B01001 | 17.6% | 17.6% | 15.7% |
| Households B11001 | 363,970 | 363,970 | 13,548,091 |
| Foreign born B05002 | 34.0% | 34.0% | 27.0% |
| Median household income B19013 | $140,970 | $140,970 | $99,122 |
| Median family income B19113 | $171,141 | $171,141 | $113,346 |
| Per capita income B19301 | $92,289 | $92,289 | $49,513 |
| Poverty rate B17001 | 11.2% | 11.2% | 12.0% |
| Unemployment rate B23025 | 6.1% | 6.1% | 6.6% |
| Civilian labor force B23025 | 507,262 | 507,262 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.4 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 60.3% | 60.3% | 37.1% |
| Housing units B25001 | 414,602 | 414,602 | 14,644,735 |
| Owner-occupied B25003 | 38.2% | 38.2% | 55.9% |
| Renters B25003 | 61.8% | 61.8% | 44.1% |
| Median home value B25077 | $1,394,500 | $1,394,500 | $734,700 |
| Median gross rent B25064 | $2,476 | $2,476 | $2,036 |
| White, not Hispanic B03002 | 36.8% | 36.8% | 33.8% |
| Black B03002 | 4.7% | 4.7% | 5.2% |
| Hispanic or Latino B03002 | 16.2% | 16.2% | 40.2% |
| Asian B03002 | 34.9% | 34.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.
Comments